MAY 2PostersSunday MorningPO-186: 3PO-187: 3PO-188: 3PO-189: 3PO-190: 3PO-191: 3PO-192: 3Long-Term Beneficial Effects on DiabeticRetinopathy of a Therapeutic Regimen Based onUltrahigh Doses of C<strong>and</strong>esartanPedro Ar<strong>and</strong>a, 1 Angel Cilvetti, 2 Jose Carlos Fern<strong>and</strong>ez-Garcia, 3 Margarita Lapeira, 2 Cristina Jironda, 1Carmen Cobelo, 1 Domingo Hern<strong>and</strong>ez. 1 1 NephrologyDepartment, Carlos Haya University General Hospital,Malaga, ES; 2 Ophthalmology Department, HospitalVirgen de la Victoria, Malaga, ES <strong>and</strong> 3 EndocrinologyDepartment, Carlos Haya University General Hospital,Malaga, ES.Antiproteinuric Effects of a Switched TherapeuticRegimen Based on Irbesartan Alone or inCombination with Aliskiren in Overt DiabeticNephropathyPedro Ar<strong>and</strong>a, 1 Carmen Cobelo, 1 Cristina Jironda, 1Jose Carlos Fern<strong>and</strong>ez-Garcia, 2 Miguel Angel Frutos, 1Domingo Hern<strong>and</strong>ez. 1 1 Nephrology Department,Carlos Haya University General Hospital, Malaga,ES <strong>and</strong> 2 Endocrinology Department, Carlos HayaUniversity General Hospital, Malaga, ES.Prevalence, Management <strong>and</strong> Control of DiabetesMellitus <strong>and</strong> Associated Risk Factors in the PrimaryHealth Care in PortugalNuno Cortez-Dias, 1 Suzana R. Martins, 1 Adriana Belo, 2Manuela Fiuza. 1 1 University Hospital Santa Maria,Lisbon, PT <strong>and</strong> 2 Portuguese Society of Cardiology,Lisbon, PT.The Relationship between Blood Pressure Control<strong>and</strong> Serum Cholesterol Levels in Type 2 DiabeticPatientsJose Diaz-Benito, Luisa Muñoz-Garde. ServicioNavarro de Salud, Pamplona, Navarra, ES.Different Effects of Aliskiren <strong>and</strong> Losartan onFibrinolysis <strong>and</strong> Insulin Sensitivity in HypertensivePatients with Metabolic SyndromeRoberto Fogari, Ilaria Ferrari, Amedeo Mugellini,Sibilla Salvadeo, Annalisa Zoppi, Paola Preti, GiuseppeDerosa. Department of Internal Medicine, Universityof Pavia, Pavia, IT.Hypertension <strong>and</strong> Diabetes BurdenWallace Johnson, 1 Gabriel E. Shaya. 2 1 University ofMaryl<strong>and</strong> School of Medicine, Baltimore, MD, US <strong>and</strong>2 Georgetown University, Washington, DC, US.Poor Antihypertensive Control of Diabetics inFinnish General Practice Seems Not to be Associatedwith Diabetic Control But Insufficient Medication<strong>and</strong> ComplianceIlkka M. Kantola†, 1 Juha Varis, 1 Lassi Nelimarkka, 1Heljä Savola, 1 Risto Vesalainen. 2 1 Turku UniversityHospital, Turku, FI <strong>and</strong> 2 Medical Centre Pulssi, Turku,FI.1 Pathobiology Track 2 Translational Track 3 Therapy Track136
Sunday Morning MAY 2PostersPO-193: 3PO-194: 3PO-195: 3PO-196: 3PO-197: 2PO-198: 2PO-199: 2Effects of an Amlodipine-<strong>and</strong> OlmesartanMedoxomil-Based Titration Regimen in Patientswith Hypertension, Type 2 Diabetes <strong>and</strong> MetabolicSyndromeVenkata S. Ram†, 1 Richard A. Sachson, 2 ChunlinQian, 3 Maninee Patel, 3 Kathy A. Stoakes. 3 1 Universityof Texas Southwestern Medical Center, US; 2 EndocrineAssociates of Dallas, US <strong>and</strong> 3 Daiichi Sankyo, Inc., US.The Influence of Simvastatin <strong>and</strong> Tiotriazolin onPlasma Resistin Levels in Patients with DiabetesMellitus <strong>and</strong> Metabolic Syndrome <strong>and</strong> Heart FailureNadia V. Skrypnik, Mariya A. Orynchak. Ivano-Frankivsk National Medical University, Ivano-Frankivsk, UA.The Metabolic Syndrome is a Risk Factor forResistant HypertensionKonstantinos Tziomalos, Maria Baltatzi, EliasEfthymiou, Konstantia Psianou, Natalia Papastergiou,Dimitria Magkou, Georgios Zervopoulos, GiannisKagelidis, Evangelia Karlafti, Christos Savopoulos,Apostolos I. Hatzitolios. First Propedeutic Departmentof Internal Medicine, Medical School, AristotleUniversity of Thessaloniki, AHEPA Hospital, GR.Global Cardiovascular Risk Control in Patients withDiabetes of Long DurationJose F. Varona, 1,2 Pedro Pablo, 3 L. Cabrerizo, 4 J. M.Miralles, 5 MELODY Study Group Investigators. 61 University Hospital Madrid Monteprincipe, Madrid,ES; 2 Medical Department, Pfizer, ES; 3 Hospital GeneralGran Canaria, ES; 4 Hospital Clinico, Madrid, ES;5 University Hospital Salamanca, ES <strong>and</strong> 6 MelodyStudy, ES.Differences in the Impact of Metabolic SyndromeComponents Among Hypertensives Attended inVarious Medical SpecialitiesAlej<strong>and</strong>ro de la Sierra†, 1 Eduardo Alegría, 2 AlbertoMartinez-Castelao, 3 Carlos Morillas, 4 Diego Gonzalez-Segura. 5 1 Hospital Mutua Terrassa, University ofBarcelona, Terrassa, ES; 2 Clinica Universitaria Navarra,Pamplona, ES; 3 Hospital Universitario Bellvitge,Barcelona, ES; 4 Hospital Universitario Dr. Pesset,Valencia, ES <strong>and</strong> 5 Almirall, Barcelona, ES.Prediabetes is Associated with Functional <strong>and</strong>Structural Cardiovascular AbnormalitiesDaniel A. Duprez, Natalia Florea, Wei Zhong, GregoryGr<strong>and</strong>its, Lynn Hoke, Jay N. Cohn. University ofMinnesota, Minneapolis, MN, US.Left Ventricular Mass <strong>and</strong> the Role of MetabolicSyndrome in Overweight/Obese HypertensivePatientsFederico Guerra, Luca Angelini, Lucia Mancinelli,Marco Fortunati, Paolo Lorenzo Dessì-Fulgheri,Aless<strong>and</strong>ro Rappelli, Riccardo Sarzani. Dept. InternalMedicine, University Ancona - Politecnica Marche,Ancona, IT.1 Pathobiology Track 2 Translational Track 3 Therapy Track137
- Page 1 and 2:
American Society of Hypertension201
- Page 3 and 4:
Valturna offers bothsuperior BP eff
- Page 5 and 6:
Figure 2: Probability of Achieving
- Page 7 and 8:
potential for other drugs acting on
- Page 9 and 10:
aliskiren arms were about one-third
- Page 11 and 12:
As with other drugs that block angi
- Page 13:
American Society of Hypertension201
- Page 18:
Program Color KeyThe pages of this
- Page 21 and 22:
General InformationThis program boo
- Page 23 and 24:
General Information continuedHilton
- Page 25 and 26:
General Information continuedASH Sc
- Page 27 and 28:
General Information continuedASH Hy
- Page 29 and 30:
2010 ASH Corporate MembersBoehringe
- Page 31 and 32:
ASH Leadership2009-2010 Board of Di
- Page 33 and 34:
Special LectureMonday, May 3, 2010,
- Page 35 and 36:
Special LectureMonday, May 3, 2010,
- Page 37 and 38:
2010 Abstract Reviewers continuedEr
- Page 39 and 40:
Visit TEKTURNA at Booth 1100.and/or
- Page 41 and 42:
5.5 HyperkalemiaIncreases in serum
- Page 43 and 44:
with Pgp substrates or weak to mode
- Page 45 and 46:
ASH Program at a GlanceSaturday, Ma
- Page 47 and 48:
ASH Program at a GlanceMonday, May
- Page 49 and 50:
Poster Category PresentationPosters
- Page 51 and 52:
2010 ASH Faculty continuedJeffrey R
- Page 53 and 54:
2010 ASH Faculty continuedAndrew Wh
- Page 55 and 56:
2010American Societyof Hypertension
- Page 57 and 58:
Saturday Afternoon MAY 1PostersPost
- Page 59 and 60:
Saturday Afternoon MAY 1Sessions3:3
- Page 61 and 62:
Saturday Afternoon MAY 1Sessions3:3
- Page 63 and 64:
Sunday Morning MAY 2Satellite Sympo
- Page 65 and 66:
Sunday Morning MAY 2Sessions contin
- Page 67 and 68:
Sunday Morning MAY 2Sessions8:00 AM
- Page 69 and 70:
Sunday Morning MAY 2Sessions10:00 A
- Page 71 and 72:
Sunday Morning MAY 2Sessions10:00 A
- Page 73 and 74:
Sunday Afternoon MAY 2Sessions3:30
- Page 75 and 76:
Sunday Afternoon MAY 2Sessions3:30
- Page 77 and 78:
Sunday Afternoon MAY 2Special Sessi
- Page 79 and 80:
Sunday Evening MAY 2Sessions6:00 PM
- Page 81 and 82:
Sunday Evening MAY 2Sessions6:00 PM
- Page 83 and 84:
Monday Morning MAY 3Satellite Sympo
- Page 85 and 86:
Monday Morning MAY 3Sessions8:00 AM
- Page 87 and 88: Monday Morning Afternoon MAY 21 3Po
- Page 89 and 90: Monday Morning MAY 3Sessions10:00 A
- Page 91 and 92: Monday Morning MAY 3Sessions10:00 A
- Page 93 and 94: Monday Morning MAY 3Sessions11:45 A
- Page 95 and 96: Monday Evening May 3Satellite Sympo
- Page 97 and 98: Tuesday Morning May 48:45 AM LB-OR-
- Page 99 and 100: Tuesday Morning May 4Sessions8:00 A
- Page 101 and 102: Tuesday Morning MAY 4ASH Membership
- Page 103 and 104: Tuesday Morning MAY 4Sessions10:55
- Page 105 and 106: 2010American Societyof Hypertension
- Page 107 and 108: Saturday Afternoon MAY 1Posters3:00
- Page 109 and 110: Saturday Afternoon MAY 1PostersPO-2
- Page 111 and 112: Saturday Afternoon MAY 1PostersPO-3
- Page 113 and 114: Saturday Afternoon MAY 1PostersPO-4
- Page 115 and 116: Saturday Afternoon MAY 1PostersPO-5
- Page 117 and 118: Saturday Afternoon MAY 1PostersPO-7
- Page 119 and 120: Saturday Afternoon MAY 1PostersPO-8
- Page 121 and 122: Saturday Afternoon MAY 1PostersPO-9
- Page 123 and 124: Saturday Afternoon MAY 1PostersPO-1
- Page 125 and 126: Sunday Morning MAY 2PostersPosters
- Page 127 and 128: Sunday Morning MAY 2Posters9:00 AM
- Page 129 and 130: Sunday Morning MAY 2PostersPO-123:
- Page 131 and 132: Sunday Morning MAY 2PostersPO-137:
- Page 133 and 134: Sunday Morning MAY 2PostersPO-150:
- Page 135 and 136: Sunday Morning MAY 2PostersPO-163:
- Page 137: Sunday Morning MAY 2PostersPO-178:
- Page 141 and 142: Sunday Morning MAY 2PostersPO-206:
- Page 143 and 144: Monday Morning Afternoon MAY 21 3Po
- Page 145 and 146: Monday Morning Afternoon MAY 21 3Po
- Page 147 and 148: Monday Morning Afternoon MAY 21 3Po
- Page 149 and 150: Monday Morning Afternoon MAY 21 3Po
- Page 151 and 152: Monday Morning Afternoon MAY 21 3Po
- Page 153 and 154: Monday Morning Afternoon MAY 21 3Po
- Page 155 and 156: Monday Morning Afternoon MAY 21 3Po
- Page 157 and 158: Monday Morning Afternoon MAY 21 3Po
- Page 159 and 160: Monday Morning Afternoon MAY 21 3Po
- Page 161 and 162: Monday Morning Afternoon May 213Pos
- Page 163 and 164: Faculty Disclosure ListingGail Adle
- Page 165 and 166: Faculty Disclosure Listing continue
- Page 167 and 168: Faculty Disclosure Listing continue
- Page 169 and 170: Faculty Disclosure Listing continue
- Page 171 and 172: Faculty Disclosure Listing continue
- Page 173 and 174: you to attend thethe Innovations Th
- Page 175 and 176: 5.5 HyperkalemiaIncreases in serum
- Page 177 and 178: with Pgp substrates or weak to mode
- Page 179 and 180: Valturna (aliskiren and valsartan,
- Page 181 and 182: 4 CONTRAINDICATIONSNone.5 WARNINGS
- Page 183 and 184: een reported. In a 4-day trial of v
- Page 185 and 186: 7 DRUG INTERACTIONSNo drug interact
- Page 187 and 188: 8.5 Geriatric UseIn 8.5the Geriatri
- Page 189 and 190:
2010 ASH ExhibitorsASH Hypertension
- Page 191 and 192:
ASH Hypertension Resource CenterHil
- Page 193 and 194:
2010 ASH Exhibitors continuedCVRx I
- Page 195 and 196:
2010 ASH Exhibitors continuedIntern
- Page 197 and 198:
2010 ASH Exhibitors continuedNature
- Page 199 and 200:
2010 ASH Exhibitors continuedRESPeR
- Page 201 and 202:
Author IndexAAbaunza, Ricardo, 122A
- Page 203 and 204:
Author IndexCastellano, Maurizio, 1
- Page 205 and 206:
Author IndexGuarneri, Marco, 146Guo
- Page 207 and 208:
Author IndexLekakis, John, 118, 122
- Page 209 and 210:
Author IndexPittaras, Andreas, 149P
- Page 211 and 212:
Author IndexTello, Susana, 109, 135
- Page 213 and 214:
Hilton New York Floor PlansSecond F
- Page 215 and 216:
Hilton New York Floor PlansFourth F
- Page 218:
Are You 1in 3?Get the facts. Know y